Preoperative Anxiety Experienced by the Pediatric Patient

2

Review clinical trials related to Preoperative Anxiety Experienced by the Pediatric Patient. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Children of Age 2-6years Undergoing Elective Surgery Will be Divided Into Two Groups Randomly. This Study Aims to Evaluate if Intranasal Dexmedetomidine is Better Than Intranasal Ketamine in Producing Sedation and Reducing Parent Separation Anxiety Before Surgery.

This study aims to compare intranasal dexmedetomidine versus intranasal ketamine as a premedication in children undergoing surgery in our population. Hypothesis is Intranal dexmedetomidine is better than intranasal ketamine in producing preoperative sedation in pediatric patients undergoing surgery under general anesthesia.

Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 2-6Biological sex: AllType: InterventionalSponsor: Liaquat National Hospital & Medical CollegeUpdated: Sep 18, 2025
Eligibility criteria

American society of Anesthesiologist (ASA) class-I and II [+1]

Known hypersensitivity to study drugs [+5]

Status: Not yet recruiting

Comparing Two Doses of Midazolam With Added Dexmedetomidine for Kids Before Surgery

The goal of this this randomized controlled trial is to investigate if adding intranasal dexmedetomidine to two different doses of intranasal midazolam provides effective sedation with fewer side effects in pediatric patients aged 1 to 8 years undergoing elective surgeries. The main questions it aims to answer are: Does combining intranasal dexmedetomidine with a reduced dose of midazolam achieve adequate sedation while minimizing adverse effects? How do different dosing regimens affect mask acceptance, parent separation, sedation levels, recovery times, and perioperative adverse events? Researchers will compare two groups: one receiving dexmedetomidine plus a higher dose of midazolam (0.4 mg/kg) and another receiving dexmedetomidine plus a lower dose of midazolam (0.2 mg/kg) to see if the reduced dose maintains sedation effectiveness while reducing side effects. Participants will: Receive intranasal dexmedetomidine (2 mcg/kg) combined with either 0.4 mg/kg or 0.2 mg/kg of intranasal midazolam. Undergo sedation scoring at 15 and 30 minutes after drug administration. Be assessed for ease of separation from parents and acceptance of anesthesia mask. Be monitored for vital signs, recovery times, and any perioperative adverse events.

Participants needed: 60
Trial details
Phase: Phase 2Age: 1-8Biological sex: AllType: InterventionalSponsor: Cairo UniversityUpdated: May 20, 2025Locations: 2
Eligibility criteria

Pediatric patients aged 1 to 8 years [+4]

Refusal to participate by parent/guardian [+11]